Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: Guidelines abound, but where are the data?

Amir Azarbal, Leonardo Clavijo, Michael A. Gaglia

    Research output: Contribution to journalReview article

    12 Scopus citations

    Abstract

    Antiplatelet therapy is invariably prescribed for patients with peripheral arterial disease and critical limb ischemia, and numerous major society guidelines espouse their use, but high-quality data in this high-risk and challenging patient population are often lacking. This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes.

    Original languageEnglish (US)
    Pages (from-to)144-156
    Number of pages13
    JournalJournal of Cardiovascular Pharmacology and Therapeutics
    Volume20
    Issue number2
    DOIs
    StatePublished - Mar 14 2015

    Keywords

    • antiplatelet therapy
    • aspirin
    • clopidogrel
    • critical limb ischemia
    • peripheral arterial disease heart disease

    ASJC Scopus subject areas

    • Pharmacology
    • Cardiology and Cardiovascular Medicine
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: Guidelines abound, but where are the data?'. Together they form a unique fingerprint.

  • Cite this